Gulanski B

References (6)

Title : Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group - Blass_2000_Alzheimer.Dis.Assoc.Disord_14_39
Author(s) : Blass JP , Cyrus PA , Bieber F , Gulanski B
Ref : Alzheimer Disease & Associated Disorders , 14 :39 , 2000
PubMedID: 10718203

Title : Metrifonate treatment of AD: influence of APOE genotype - Farlow_1999_Neurology_53_2010
Author(s) : Farlow MR , Cyrus PA , Nadel A , Lahiri DK , Brashear A , Gulanski B
Ref : Neurology , 53 :2010 , 1999
PubMedID: 10599773

Title : Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease - Pettigrew_1998_J.Clin.Pharmacol_38_236
Author(s) : Pettigrew LC , Bieber F , Lettieri J , Wermeling DP , Schmitt FA , Tikhtman AJ , Ashford JW , Smith CD , Wekstein DR , Markesbery WR , Orazem J , Ruzicka BB , Mas J , Gulanski B
Ref : Journal of Clinical Pharmacology , 38 :236 , 1998
PubMedID: 98210831

Title : Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group [see comments] [published erratum appears in Neurology 1998 Jul\;51(1):332] - Cummings_1998_Neurology_50_1214
Author(s) : Cummings JL , Cyrus PA , Bieber F , Mas J , Orazem J , Gulanski B
Ref : Neurology , 50 :1214 , 1998
PubMedID: 9595966

Title : Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study - Cutler_1998_Life.Sci_62_1433
Author(s) : Cutler NR , Jhee SS , Cyrus P , Bieber F , TanPiengco P , Sramek JJ , Gulanski B
Ref : Life Sciences , 62 :1433 , 1998
PubMedID: 9585171

Title : Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease [see comments] - Morris_1998_Neurology_50_1222
Author(s) : Morris JC , Cyrus PA , Orazem J , Mas J , Bieber F , Ruzicka BB , Gulanski B
Ref : Neurology , 50 :1222 , 1998
PubMedID: 9595967